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background:  Algorithms to predict the future long-term risk of patients with stable coronary artery disease (CAD) are rare. The VIenna and 
Ludwigshafen CAD (VILCAD) risk score was one of the first scores specifically tailored for this clinically important patient population. We aimed to 
refine risk prediction in stable CAD creating a new prediction model encompassing various pathophysiologic pathways. We therefore assessed 135 
novel biomarkers for long-term mortality in stable CAD patients.
methods:  We included 1275 stable CAD patients of the LUdwigshafen RIsk and Cardiovascular health (LURIC) study with a median follow-up of 9.8 
years to investigate whether the predictive power of the VILCAD score could be improved by the addition of novel biomarkers. Additional biomarkers 
were selected in a bootstrapping procedure based on Cox regression to determine the most informative predictors for mortality.
results:  The final multivariable model encompassed nine clinical and biochemical markers: age, sex, left ventricular ejection fraction (LVEF), heart 
rate, NT-proBNP, cystatin C, renin, 25OH-vitamin D3 and HbA1c. The extended VILCAD biomarker score achieved a significantly improved C-statistic 
(0.78vs.0.73;P=0.035) and net reclassification index (14.9%;P<0.001) compared to the original VILCAD score. Omitting LVEF, which might not be 
readily available, slightly reduced the accuracy of the new BIO-VILCAD score but still significantly improved risk classification (NRI: 12.5%;P<0.001).
conclusions:  The VILCAD biomarker score based on routine parameters complemented by novel biomarkers outperforms previous risk algorithms 
and allows more accurate classification of stable CAD patients enabling physicians to choose more personalized treatment regimens for their 
patients.
